Chemotherapy News and Research

Latest Chemotherapy News and Research

Aggressive treatment of T3 and T4 NSCLC with induction chemoradiotherapy may improve survival

Researchers from Boston University School of Medicine (BUSM) have found that patients with node negative T3 and T4 non-small lung cancer who underwent chemotherapy before surgery had more than three times the survival rate than patients who only underwent surgery. These findings currently appear on-line in the Journal of Thoracic and Cardiovascular Surgery.

1 Mar 2011

Mindray Medical enters agreement to acquire controlling stake of Shenke

Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today an agreement to acquire a controlling stake of Shenzhen Shenke Medical Instrument Technical Development Co. Ltd. The terms of the transaction were not disclosed as the transaction is non-material to Mindray's financial statements.

From Mindray 28 Feb 2011

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer

ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced today that it has filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase 3 trial of telatinib in combination with chemotherapy for the first-line treatment of patients with advanced stomach cancer.

28 Feb 2011

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics, Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for the use of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.

28 Feb 2011

Study: Fish oil may prevent muscle and weight loss in cancer patients during chemotherapy

A new analysis has found that supplementing the diet with fish oil may prevent muscle and weight loss that commonly occurs in cancer patients who undergo chemotherapy. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that fish oil may help combat cancer-related malnutrition.

28 Feb 2011

Innovative miniscule gene transport system can cause breast cancer cells to self-destruct

Scientists at Queen's University Belfast have shown that they can deliver a gene directly into breast cancer cells causing them to self-destruct, using an innovative, miniscule gene transport system, according to research published today in the International Journal of Pharmaceutics.

28 Feb 2011

Phase III trial results: Erlotinib has comparable efficacy to chemotherapy with better tolerability against lung cancer

The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial show.

27 Feb 2011

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that encouraging preliminary results of a Phase 2 trial of ganetespib as a single agent in non-small cell lung cancer were presented at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

27 Feb 2011

Avastin debate spills over until June FDA hearing

The U.S. Food and Drug Administration have granted Roche a hearing in June to defend the cancer treatment Avastin. The hearing would examine the effectiveness of the drug in breast cancer.

27 Feb 2011

Less-toxic combination of immune-based drug and chemotherapy drug produce long-term remissions in CLL

New research shows that a less-toxic combination of a targeted immune-based drug and a chemotherapy drug can produce long-term remissions in some chronic lymphocytic leukemia patients. And it does so without increasing the risk of later therapy-related myelodysplastic syndrome and acute myeloid leukemia, which can often occur with a three-drug combination used to treat these patients.

25 Feb 2011

Researchers capture complexities of breast cancer tumours to improve treatment, diagnostics

Breast cancer can develop very differently in different women. Researchers in Norway are improving breast cancer diagnostics and treatment by identifying the various tumour types. The objective is to find out as much as possible about the various tumour types so that each patient can receive precisely the right treatment at the right time.

25 Feb 2011

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, today announced the U.S. Food and Drug Administration (FDA) has granted a hearing to allow the company the opportunity to present its views on why Avastin® (bevacizumab) should remain FDA-approved for metastatic breast cancer (mBC). The FDA has scheduled the hearing for June 28 to 29, 2011.

25 Feb 2011

BSD announces inclusion of hyperthermia and chemotherapy for high-risk sarcoma cancer patients

BSD Medical Corporation today announced the inclusion of hyperthermia and chemotherapy as a recommended cancer treatment for Stage IV sarcomas in the "Practice Guidelines in Oncology", which is issued by the National Comprehensive Cancer Network.

25 Feb 2011

Feasibility study to test scalp cooling device in breast cancer patients undergoing chemotherapy

A feasibility study to test the use of a scalp cooling device that breast cancer patients will wear while undergoing chemotherapy treatment will be conducted at Wake Forest University Baptist Medical Center. This will be part of the first significant study of the medical device in the United States.

25 Feb 2011

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 2 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.

24 Feb 2011

EpiCept 2010 fourth quarter net loss is $0.06 per share

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2010, and provided an update on its key business initiatives.

24 Feb 2011

Pretreatment with FDA-approved drug allows successful pregnancies in radiation-exposed rhesus monkeys

A strategy developed by Massachusetts General Hospital (MGH) researchers to shield the ovaries of female mammals from the damaging effects of radiation and chemotherapy has passed an important milestone. A collaborative study with investigators from Oregon Health and Sciences University (OHSU), published online in the journal Fertility and Sterility, reports that brief preexposure of the ovaries to an FDA-approved agent called FTY720 preserved the fertility of female rhesus monkeys exposed to potentially lethal doses of radiation.

23 Feb 2011

Focused Ultrasound Surgery Foundation releases men's heath update on prostate cancer, BPH treatments

The Focused Ultrasound Surgery Foundation has released a special men's heath update in its February 2011 online newsletter.

23 Feb 2011

MD Anderson physician honored for impact on blood, marrow transplantation

The American Society for Blood and Marrow Transplantation has honored leader, innovator and educator Richard Champlin, M.D., with its Lifetime Achievement Award during the group's annual meeting Feb. 17-21.

23 Feb 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

Aggressive treatment of T3 and T4 NSCLC with induction chemoradiotherapy may improve survival

Mindray Medical enters agreement to acquire controlling stake of Shenke

TCD announces first patient treated in its TCD-717 Phase I trial

ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Study: Fish oil may prevent muscle and weight loss in cancer patients during chemotherapy

Innovative miniscule gene transport system can cause breast cancer cells to self-destruct

Phase III trial results: Erlotinib has comparable efficacy to chemotherapy with better tolerability against lung cancer

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

Avastin debate spills over until June FDA hearing

Less-toxic combination of immune-based drug and chemotherapy drug produce long-term remissions in CLL

Researchers capture complexities of breast cancer tumours to improve treatment, diagnostics

Genentech granted FDA hearing on Avastin for metastatic breast cancer

BSD announces inclusion of hyperthermia and chemotherapy for high-risk sarcoma cancer patients

Feasibility study to test scalp cooling device in breast cancer patients undergoing chemotherapy

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

EpiCept 2010 fourth quarter net loss is $0.06 per share

Pretreatment with FDA-approved drug allows successful pregnancies in radiation-exposed rhesus monkeys

Focused Ultrasound Surgery Foundation releases men's heath update on prostate cancer, BPH treatments

MD Anderson physician honored for impact on blood, marrow transplantation

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in